Intellia Therapeutics (NTLA) Revenue (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Revenue of $15.0 million for Q1 2026, down 9.5% year-over-year from $16.6 million in Q1 2025, and down 34.62% quarter-over-quarter from $23.0 million in Q4 2025.
Intellia Therapeutics (NTLA) Revenue (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Revenue for 12 consecutive years, with $15.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Revenue fell 9.5% year-over-year to $15.0 million; the TTM figure through Mar 2026 stood at $66.1 million (up 45.04% YoY), while the FY2025 annual figure was $67.7 million, up 16.92% from the prior year.
- Revenue slipped to $15.0 million in Q1 2026 per NTLA's latest filing, from $23.0 million in the prior quarter.
- Across five years, Revenue topped out at $28.9 million in Q1 2024 and bottomed at -$1.9 million in Q4 2023.
- Historically, Revenue has averaged $13.5 million across 5 years, with a median of $13.6 million in 2022.
- Annual changes were most pronounced in 2023 — Revenue plunged 114.12% — and 2024, when it jumped 771.57%.
- Intellia Therapeutics' Revenue stood at $13.6 million in 2022, then slumped by 114.12% to -$1.9 million in 2023, then soared by 771.57% to $12.9 million in 2024, then surged by 78.79% to $23.0 million in 2025, then tumbled by 34.62% to $15.0 million in 2026.
- Business Quant data shows NTLA's Revenue at $15.0 million in Q1 2026, $23.0 million in Q4 2025, and $13.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | 7.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.66 Mn |
| Mar 31, 2026 | 15.05 Mn |
| Dec 31, 2025 | 23.02 Mn |
| Sep 30, 2025 | 13.78 Mn |
| Jun 30, 2025 | 14.25 Mn |
| Mar 31, 2025 | 16.63 Mn |
| Dec 31, 2024 | 12.87 Mn |
| Sep 30, 2024 | 9.11 Mn |
| Jun 30, 2024 | 6.96 Mn |
| Mar 31, 2024 | 28.94 Mn |
| Dec 31, 2023 | -1.92 Mn |
| Sep 30, 2023 | 11.99 Mn |
| Jun 30, 2023 | 13.59 Mn |
| Mar 31, 2023 | 12.61 Mn |
| Dec 31, 2022 | 13.57 Mn |
| Sep 30, 2022 | 13.27 Mn |
| Jun 30, 2022 | 14.03 Mn |
| Mar 31, 2022 | 11.25 Mn |
| Dec 31, 2021 | 12.85 Mn |
| Sep 30, 2021 | 7.20 Mn |